
Opinion|Videos|May 14, 2024
Treatment Options for mHSPC
In this segment, Dr. Shore will offer an overview of current treatment options for metastatic hormone-sensitive prostate cancer (mHSPC), as outlined in the NCCN Guidelines for Prostate Cancer. He will discuss patient factors that guide the selection of therapeutic agents or combination therapies.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Relacorilant Demonstrates Significant OS in Platinum-Resistant Ovarian Cancer
2
Oncologists Weigh BTK/BCL2 Inhibitor Combinations in CLL
3
FDA OKs Guardant360 CDx for Encorafenib Combo in BRAF V600E+ Metastatic CRC
4
Later-Line and Combination Therapies in cGVHD and Future Directions
5





















